Immunology

Lucid Group expands its presence in the north-west with six new hires – PMLiVE

Healthcare 21, a Lucid Group company, continues to strengthen its editorial and medical writing team with six new additions to its Macclesfield office.

Rosanna Farrell joins HealthCare 21 as a Senior Editorial Assistant. Rosanna has 7 years experience in editorial, working with TimeOut London, The Big Issue and The London 2012 Olympics programmes.

Becca Winkle joins HealthCare 21 as an Editorial Assistant. Becca has an MA in English Literary Studies, English Literature and Literary Theory as well as previous teaching and editorial experience. Becca comments I became interested in MedComms because, as someone with a passion for English Language and Literature, I recognise the importance of the style and functionality of language when conveying information about complex subjects or issues. As an Editorial Assistant at HealthCare21, Im excited to be part of a process that ultimately leads to a better experience for healthcare professionals and patients receiving care.

Alex Nicholson joins HealthCare 21 as an Editorial Assistant. Alex has a degree in English and French and a PGCE in Modern Languages and he is currently studying for his StEP Proofreading 2: Headway. Alex previously worked as a freelance transcriber for a document service company and runs a blog on popular culture, sport and current affairs.

Nicole Scullion joins HealthCare 21 as a Trainee Medical Writer. Nicole has an MRes in Biomedical Sciences and Translation Medicine from the University of Liverpool where she focussed on cancer biology and the response of uveal melanoma.

Sophie Day also joins HealthCare 21 as a Trainee Medical Writer. Sophie has a BSc in Biology from the University of Manchester where she completed her dissertation in Science Media and Communication.

Areeba Ali joins HC21 as a trainee medical writer. Originally from Ireland she moved to Manchester to pursue a Masters in Clinical Immunology. Areeba comments, Im very excited to be joining such a people-centric organisation with such a focus on transforming patients lives.

If you are interested in being part of something magical, get in touch.

Contact Dan Newbury, Talent Acquisition ManagerEmail: Daniel@lucid-group.co.ukTel: 01494 755495

Link:
Lucid Group expands its presence in the north-west with six new hires - PMLiVE

Immunology

CIMZIA approved for use by Health Canada – Spinal News International

Syringe with Certolizumab pegol

UCB Canada has announced that CIMZIA (certolizumab pegol) for the treatment of adults with severe active non-radiographic axial spondyloarthritis (nr-axSpA), has been approved for use by Health Canada.

The treatment is targeted at adults with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).

Health Canadas approval is based on data from C-AXSPAND5, a Phase 3, multicentre, double-blind, placebo-controlled 52-week study that randomised 317 adult patients to receive either CIMZIA or placebo plus common background medications, which included NSAIDs, corticosteroids, analgesics and slow-acting anti-rheumatic drugs. The study met its primary endpoint, with 47.2% of patients treated with CIMZIA demonstrating major improvement response in Ankylosing Spondylitis Disease Activity Score (ASDAS-MI) at week 52, compared to 7.0% of patients treated with placebo. Detailed findings from the study were published online in Arthritis & Rheumatology in March 2019.

Were pleased to see this important advance for the spondyloarthritis community. Greater awareness, earlier diagnosis and more treatment options will help deliver better outcomes for Canadians living with this painful disease which often falls through the cracks, and carries with it a significant burden, said Gerald Major, president, Canadian Spondylitis Association.

The approval marks the fifth indication for CIMZIA, which is the only Fc-free, PEGylated anti-TNF option available for the treatment of the disease where significant unmet need currently exists, UCB said in a press release.

The journey patients face from symptom onset to diagnosis and receiving appropriate treatment can be extremely lengthysometimes up to 10 years. So having a new and effective option for nr-axSpA is welcome news, both for those suffering and their physicians who are seeking a proven treatment to reduce the severe pain, stiffness, and other burdensome symptoms of the disease, said Walter Maksymowych, professor and medical scientist in the Department of Medicine, Division of Rheumatology at the University of Alberta (Edmonton, Canada).

The approval of CIMZIA for nr-axSpA is an important treatment advance which builds on more than a decade of market experience and proven efficacy and safety, said Lionel Houle, head of immunology, UCB Canada.

Read this article:
CIMZIA approved for use by Health Canada - Spinal News International

Immunology

JPM, Day 3: AbbVie duo’s $20B ambitions, GSK and Pfizer’s what-next moment and Amarin’s clear runway – FiercePharma

We're not gonna lieWednesdays at the J.P. Morgan Healthcare Conference feel a bit anticlimactic. Two days of meetings, presentations, panels and cocktail hours are past, and we can see the end in sight.

But that doesn't mean the action has come to a halt. Indeed, we picked up some unprecedented talk from AbbVie CEO Rick Gonzalez first thing Wednesday morning, and by day's end had heard some even bigger numbers from a GlaxoSmithKline vaccines exec.

Now, our JPM on-site team is dispersing, recapping and digging through notebooks for quotes that captured the whirlwind conference-in-progress. Here's what we heardand what we're thinkingafter Day 3.

Artificial Intelligence in the Pharma Industry

How far has the adoption of AI technology come in Life Sciences? Share your thoughts in this brief, 8-minute survey. Let your voice be heard.

Missed our previous roundups? Here areDay 1 and Day 2. And check out our collectedJPM coverage: FierceBiotech's here and FiercePharma's here.

GlaxoSmithKline and Pfizer seem to have contradictory visions for their consumer health joint venture. During a Tuesday presentation, Pfizer chief Albert Bourla said he believes the JV is heading toward an IPO within three to four years in a move that provides the New York pharma a clear exit strategy. Maybe not, GSKs chief strategy officer David Redfern saidin an interview with Bloomberg the following day. "And its entirely our decision, Redfern said. Story

At Wednesdays first presentation, AbbVie CEO Richard Gonzalez talked up the potential of two thedrugmakersnew immunology launchesSkyriziandRinvoq. While only approved in psoriasis and rheumatoid arthritis right now, respectively, Gonzalez said he expects the meds to pick up newindications toeventually match or best Humira, AbbVies almost-$20 billionmegablockbuster. If pricing holds steady, he could envision the meds reaching $20 billion in sales or more, easily picking up where Humira leaves off as biosimilars enter the U.S.in 2023. Story

GSKsShingrixgenerated blockbuster sales quickly after its launch, but numberstouted by thedrugmakerthis weekshow the size of the remaining opportunityand how much supply constraints have held the rollout back.The company figures a massive 115 million people in the U.S. alone would be eligible for Shingrix,GSKs vaccines presidentRoger Connor toldFiercePharma at JPM. The company'slooking everywhere to increase capacity, but its started to hit a bottleneck," with true relief several years away. Story

Amarin's been revving up for Vascepa's big CVlaunch in the U.S., and now thatAstraZenecas Epanova flopped a major trial, its field is clear of competitors. In Europe, Vascepa is still awaiting its regulatory review for CV risk reduction, but that hasn't stoppedother drugmakers from sniffing around for possible licensing opportunities, CEO John Thero told investors Wednesday. Not interested, Thero saidat least not yet. Amarin sees more value in waiting out the regulatory process before considering a deal. Its still a bit premature to get too far along in these conversations as we think the value will increase as the regulatory process proceeds in Europe, he said. Story

MichaelGoettler, CEO-to-be of the newViatris, said the combination of Mylan and Upjohn will have global scale and geographic reach, and will be a partner of choice for midsizeddrugmakersseeking to reach new markets. The combination makes sense because together the companies will have a sustainable and diverse portfolio,plusstrong commercial capabilities and financialperformance,Goettlersaid.

See more here:
JPM, Day 3: AbbVie duo's $20B ambitions, GSK and Pfizer's what-next moment and Amarin's clear runway - FiercePharma

Cell Biology

Correlative three-dimensional super-resolution and block-face electron microscopy of whole vitreously frozen cells – Science Magazine

David P. Hoffman

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Gleb Shtengel

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

C. Shan Xu

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Kirby R. Campbell

Department of Developmental Neurobiology, St. Jude Childrens Research Hospital, Memphis, TN 38105, USA.

Melanie Freeman

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Lei Wang

Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.Program in Cellular and Molecular Medicine, Boston Childrens Hospital, Boston, MA 02115, USA.Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.

Daniel E. Milkie

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

H. Amalia Pasolli

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Nirmala Iyer

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

John A. Bogovic

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Daniel R. Stabley

Neuroimaging Laboratory, St. Jude Childrens Research Hospital, Memphis, TN 38105, USA.

Abbas Shirinifard

Bioimage Analysis Core, St. Jude Childrens Research Hospital, Memphis, TN 38105, USA.

Song Pang

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

David Peale

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Kathy Schaefer

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Wim Pomp

Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.Program in Cellular and Molecular Medicine, Boston Childrens Hospital, Boston, MA 02115, USA.Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.

Chi-Lun Chang

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Jennifer Lippincott-Schwartz

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Tom Kirchhausen

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.Department of Cell Biology, Harvard Medical School, Boston, MA 02115, USA.Program in Cellular and Molecular Medicine, Boston Childrens Hospital, Boston, MA 02115, USA.Department of Pediatrics, Harvard Medical School, Boston, MA 02115, USA.

David J. Solecki

Department of Developmental Neurobiology, St. Jude Childrens Research Hospital, Memphis, TN 38105, USA.

Eric Betzig

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA.Department of Physics, University of California, Berkeley, CA 94720, USA.Howard Hughes Medical Institute, Berkeley, CA 94720, USA.Helen Wills Neuroscience Institute, Berkeley, CA 94720, USA.Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA.

Harald F. Hess

Janelia Research Campus, Howard Hughes Medical Institute, Ashburn, VA 20147, USA.

Read more:
Correlative three-dimensional super-resolution and block-face electron microscopy of whole vitreously frozen cells - Science Magazine

Cell Biology

Good night’s sleep has power to turn back clock, and study could ‘unlock mysteries of ageing’ – inews

NewsScienceNow, academics have explained for the first time the mystery of why it is so replenishing to be out like a light

Wednesday, 15th January 2020, 9:39 pm

Biologists at the University of Manchester have studied mice to show how the diurnal rhythm, or body clock, can boost the ability to maintain important cell structures during the day. It is hoped the study could one day help unlock some of the mysteries of ageing.

Professor Karl Kadler, lead author of a report published in Nature Cell Biology, said: Knowing this could have implications on understanding our biology at its most fundamental level. It might give us some deeper insight into how wounds heal, or how we age.

Turning back the clock

The universitys discovery throws a light on the bodys extracellular matrix, which provides structural and biochemical support to cells in the form of connective tissue such as bone, skin, tendon and cartilage.

The researchers have discovered the body has two types of fibrils rope-like structures of collagen that are woven by the cells to form tissues.

Thicker fibrils are permanent and stay with us throughout our lives, unchanged from the age of 17. But thinner fibrils break as the body is subjected to the rigours of the day and replenishing when we get a good rest at night.

Its intuitive to think our matrix should be worn down by wear and tear, but it isnt and now we know why. Our body clock makes an element which can be replenished, Professor Kadler said.

Sleep patterns

Researchers at the same university found last year that blue light might not be as disruptive to sleep patterns as previously thought and using cooler lighting in the evening and bright warmer lights in the day may be more beneficial.

Collagen provides the body with structure and is our most abundant protein, ensuring the integrity, elasticity and strength of the bodys connective tissue, Professor Kadler said.

Its intuitive to think our matrix should be worn down by wear and tear, but it isnt and now we know why. Our body clock makes an element which can be replenished.

Go here to read the rest:
Good night's sleep has power to turn back clock, and study could 'unlock mysteries of ageing' - inews

Cell Biology

Why stem cells could be the medical innovation of the century – World Economic Forum

Right now, your bodys stem cells are working hard replacing your skin every two weeks, creating new red and white blood cells and completing thousands of other tasks essential to life. They are your own personalized fountain of youth.

Scientists generally agree that a stem cell should be able to do both of the following:

One theory of ageing suggests that between the ages of 30 and 50, our stem cells reach a turning point and start to decline in number and function. This results in the typical features associated with ageing.

There does not seem to be a single discoverer of stem cells. Accounts date back to the 1800s and even further, but the first successful medical procedure was a bone marrow transfusion in 1939. Advances in immunology led to donor matching, initially via siblings and close relatives. Unrelated donor matching flourished in the 1970s, alongside donor registries.

In the 1980s, scientists identified embryonic stem cells in mice, leading to the 1997 cloning of Dolly the Sheep. This created immense interest for human and medical applications and a backlash in the US as federal R&D funding was essentially halted in 2001.

In 2012, a Nobel Prize was awarded for the earlier discovery of induced pluripotent stem cells (iPS). Essentially, they return potency and self-renewal properties to mature non-stem cells, essentially making them act like stem cells again.

In the decade between 2010 and 2019, the first wave of stem cell start-ups emerged, alongside R&D programmes at many large pharmaceutical companies, leading to innovation and the first human clinical trials for iPS and other related therapies.

According to Q3 2019 data from the Alliance for Regenerative Medicine, there are 959 regenerative medicine companies worldwide sponsoring 1,052 active clinical trials; 525 of these companies are in North America, 233 in Europe and Israel, and 166 in Asia. In aggregate, $7.4 billion has been invested in regenerative medicine companies in 2019; $5.6 billion of which has been dedicated to gene and gene-modified cell therapy, $3.3 billion in cell therapy, and $114 million in tissue engineering.

Overview of the cancer stem cells market

Perhaps most excitingly, curative therapies are hitting the market and the results are astonishing: 60% of Acute Lymphoblastic Leukemia patients taking Novartis Kymirah showed a complete response (no traces of cancer) and were declared in full remission. Meanwhile, 75% of patients with Transfusion-Dependent -Thalassaemia treated with bluebird bios Zynteglo achieved independence from transfusions. Perhaps most astonishingly, 93% of spinal muscular atrophy patients treated with Novartis Zolgensma were alive without permanent ventilation 24 months after treatment. We should expect more medical breakthroughs in the coming years.

New science, new start-ups: several companies in the sector have gone public or been acquired. These exits led to the recycling of talent and capital into new companies. Because the science and commercial systems have also advanced, the companies in the next wave are pursuing bigger challenges, driving innovation, with even greater resources.

Patients are eager: the current market for stem cell therapies is growing at 36% per year, though it will rapidly expand when a breakthrough occurs toward the treatment of a non-communicable disease (such as cancer, diabetes, heart disease) or a lifestyle factor (for example, growing hair in the correct places, expanding cognitive abilities or increasing healthy lifespan).

New R&D models: funding is flowing into the sector from large companies, VC funds, and institutions such as the California Institute for Regenerative Medicine (CIRM) and New York State Stem Cell Science programme (NYSTEM). Some of the leading university R&D platforms include the Center for the Commercialization of Regenerative Medicine in Toronto, the Stanford Institute for Stem Cell Biology and Regenerative Medicine, the Oxford Stem Cell Institute, and most notably, the Harvard Stem Cell Institute (HSCI).

Founded in 2004, HSCI has established a phenomenal track record. It provided the first $200,000 in funding to Derrick Rossis lab, which inspired the largest biotech IPO to date. HSCI scientists were also co-founders or principals in the three most prominent gene-editing companies (CRISPR Tx, Intellia and Editas), the combined $1.55-billion True North/iPierian acquisitions and the recent $950-million acquisition of Semma Tx, Frequency Tx, Fate Tx, Epizyme Inc., and Magenta Tx.

For the casual investor, Evercore ISI is building a Regenerative Medicine Index, which may be the simplest way to build a portfolio. For institutions and those with deeper pockets, regenerative medicine funds are forming, including the Boston-centric Hexagon Regenerative Medicine Fund, which aims to create companies out of the Harvard Stem Cell Institute.

Caveat emptor. Though patients needs are immediate, those seeking treatments should think very carefully about the risks. There are many dubious clinics touting expensive stem cell treatments and some patients have experienced horrifying complications. Dr. Paul Knoepfler of UC-Davis has written a practical and scientifically accurate guide, a strongly recommended read if you or a family member are considering treatment or a clinical trial.

The leading causes of death in 1900 were mostly infectious/communicable diseases. While the prevalence of most causes has diminished, the largest increases include heart disease (+40%) and cancer (+300%). Granted, this is partly due to doubling life expectancy and a lack of death from other causes. However, given time and resources, scientists and physicians may cure these challenging diseases.

Total disease burden by disease or injury

Today, six of the seven leading causes of death are non-communicable diseases (heart disease, stroke, lung diseases, cancer, Alzheimers disease and diabetes). Based on the early promise mentioned above, regenerative medicine may be our best hope to solve the great non-communicable diseases of our time, and perhaps the single most transformative medical innovation in a century.

License and Republishing

World Economic Forum articles may be republished in accordance with our Terms of Use.

The views expressed in this article are those of the author alone and not the World Economic Forum.

See original here:
Why stem cells could be the medical innovation of the century - World Economic Forum

Cell Biology

Aberdeenshire schools urged to get creative and light the north – Buchan Observer

Schools and community youth groups are being asked to get involved with a creative north-east sculpture and education programme.

The leading cancer support and wellbeing charity, CLAN Cancer Support, is looking for young people to get involved with the Little Lights Education programme, which will run alongside the Light the North lighthouse trail.

The trail will take place in Autumn 2020 and will see 8 ft high decorated lighthouses and mini lighthouse sculptures across Aberdeen and Aberdeenshire, Moray, Orkney and Shetland.

The Little Lights Education Programme links to the Curriculum for Excellence with all participating schools and community groups being provided with a creative learning resource pack.

The pack contains a programme of study designed to complement teaching of numerous subjects including the history and development of lighthouses, a link to the sea including renewables and wider energy sector, maritime, cell biology, physical health and emotional wellbeing with a focus on the development of personal resilience.

Iona Mitchell, CLANs head of cancer support services, said: Numerous schools and community youth groups have noted their interest in the Little Lights programme, and we are encouraging more to take part, before the final deadline on January 31.

The education programme is fascinating as it gives a real insight into the lighthouses of the north-east and our relationship with the sea. Furthermore, the pack contains age-appropriate information about cancer. A diagnosis of cancer, in a family, can have a significant impact on a childs emotional wellbeing.

"The Little Lights Education Programme aims to empower our future adults to manage their physical and emotional wellbeing and develop personal resilience which will provide them with lifelong strategies to employ, which will help them navigate through difficult times.

After getting creative in the classroom, teachers, parents and young people will see their 3D masterpiece on the art trail alongside those of contemporary artists at museums, libraries, galleries and leisure venues. After 10 weeks on public display, each little lighthouse sculpture will go back to the school or community to keep.

We urge schools and communities to be part of this unique event that will raise vital funds for CLAN Cancer Support and deliver significant benefits to teachers, pupils, and our community.

The deadline for schools taking part in the programme is January 31. To take part schools and community groups should visit http://www.lightthenorth.co.uk where they can download an education pack.

More here:
Aberdeenshire schools urged to get creative and light the north - Buchan Observer

Cell Biology

Special delivery: McMaster physicists design super-human red blood cells to deliver drugs to specific targets within the body – Newswise

MEDIA CONTACT

Available for logged-in reporters only

Newswise A team of physicists from McMaster University has developed a process to modify red blood cells so they can be used to distribute drugs throughout the body, which could specifically target infections or treat catastrophic diseases such as cancer or Alzheimers.

The modified red blood cells are designed to circulate in the body for several weeks at a time, seeking out specific targets including bacteria, tumours or organs.

The technology, described in the online edition of the journal Advanced Biosystems, solves a major problem with current drug delivery methods that use synthetic molecules and cannot reach specific targets or are rejected by the body.

We call these super-human red blood cells. We think that they could work as the perfect stealth drug carriers which can outsmart our immune system, explains Maikel Rheinstdter, a senior advisor on the study and professor in the Department of Physics & Astronomy at McMaster.

The researchers have developed a method to open up the red blood cell, modify its outer cell wall, and replace its contents with a drug molecule, which would then be injected back into the body.

The hybrid appears and behaves as a normal red blood cell, but has a sticky surface which can attach itself to bacteria, for example, open up and release antibiotics exactly where they are needed.

We have combined synthetic material with biological material and created a new structure, which has never been done before in this way, says Sebastian Himbert, lead author and a graduate student in the Department of Physics & Astronomy at McMaster.

The entire process is very efficient and can be completed in one day in the lab, he says.

Researchers believe this targeted delivery method could help to minimize dosages and therefore, potential side effects. This is particularly important for very potent drugs used in cancer and Alzheimers disease, and the treatment of infections of potentially resistant bacteria.

The work was done in collaboration with Harald Stver, professor in the Department of Chemistry and Chemical Biology at McMaster, Janos Juhasz from the Juravinski Cancer Centre, and researchers at Saarland University in Germany.

A high res photo and video of researchers Maikel Rheinstdter and Sebastien Himbert can be found at this link: https://assets.adobe.com/public/907bc03f-19a0-4454-6dda-d1d10a57eb0a

Attention editors: A copy of the study can be found at the link below:

Adv. Biosys.2020, 1900185 Hybrid erythrocyte liposomes: functionalized red blood cell membranes for molecule encapsulation, Sebastian Himbert, Matthew J. Blacker, Alexander Kihm, Quinn Pauli, Adree Khondker, Kevin Yang, Sheilan Sinjari, Mitchell Johnson, Janos Juhasz, Christian Wagner, Harald D. H. Stver and Maikel C. Rheinstdter

Adv. Biosys.2020, 1900185

https://doi.org/10.1002/adbi.201900185

SEE ORIGINAL STUDY

Go here to see the original:
Special delivery: McMaster physicists design super-human red blood cells to deliver drugs to specific targets within the body - Newswise

Cell Biology

Artisan Bio Announces Global Research and Discovery Collaboration Agreement with Takeda to Develop Next-Generation Cell Therapy Products | More News |…

DetailsCategory: More NewsPublished on Wednesday, 15 January 2020 15:24Hits: 501

Multi-target collaboration combines Artisan Bio's proprietary synthetic biology platform with Takeda's Cell Therapy Expertise

DENVER, CO, USA I January 15, 2020 I Artisan Bio, Inc., a stealth cell therapy engineering company, today announced it has entered into a global research and collaboration agreement with Takeda Pharmaceutical Company Limited ("Takeda") for the discovery, development, and commercialization of novel cell therapy products.

Under the terms of the agreement, Artisan Bio will deploy its STAR platform and synthetic biology expertise to construct customized and precisely engineered cell therapies. Artisan will lead discovery efforts, including gene editing, and Takeda will be responsible for the development, manufacturing, and commercialization of the resulting cell therapy products.

"We are thrilled to collaborate with Takeda and combine our advanced cell engineering capabilities with Takeda's visionary cellular therapy programs," said Ryan T. Gill, CEO of Artisan Bio. "Many limitations that exist in current generation cell therapies can be addressed through the precision engineering of cells for enhanced performance. This collaboration will accelerate the availability of more effective next-generation cellular therapies for patients with high unmet needs."

About Artisan Bio:Artisan's vision is to design, build, and deliver cells and precision engineering processes thatadvance cellular therapies across a broad range of human health indications. The company's designer cell engineering and data analysisSTARplatform enables partners to more rapidly and cost effectively generate safer and more efficacious cell therapies. By engaging in strategic collaborations with innovativepartners, Artisan seeks to deliver customizable cellengineering solutions that meet the complexitiesassociatedwith next-generation cell therapies. Artisan has offices in Denver, Colorado and Copenhagen, Denmark.

For more information, please visithttp://artisancells.com/.

SOURCE: Artisan Bio

Read the original:
Artisan Bio Announces Global Research and Discovery Collaboration Agreement with Takeda to Develop Next-Generation Cell Therapy Products | More News |...